Inhibitex has announced that the FDA has granted Aurexis, its humanized monoclonal antibody, fast track designation.
In the Pipeline
- Inhibitex has announced that the FDA has granted Aurexis, its humanized monoclonal antibody, fast track designation. Aurexis is being evaluated in a Phase II clinical trial for the first-line treatment of serious hospital-associated Staphylococcus aureus bloodstream infections.
- Favrille has initiated a Phase III clinical trial (FavId-06) evaluating the company’s lead product candidate, FavId. FavId, an active immunotherapy, is being studied as a potential therapy for the treatment of follicular B-cell non-Hodgkin’s lymphoma.
- Cardiome Pharma Corp. has initiated subject dosing in its Phase I study of a controlled release formulation of oral RSD1235, which is being developed as a chronic treatment for atrial fibrillation.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.